retatrutide phase 2 trial results weight loss for loss: Study shows 30% body weight The FDA has issued warning

A recent study found that patients with type 2 diabetes taking a GLP-1 receptor agonist (such as Mounjaro) may be at an increased risk for developing the debilitating condition

There is also an increase in the amount of glycated Hb

Key takeaways BPC-157 refers to the peptide sequence originally studied in preclinical research, while BPC-Lx Pro applies that BPC concept in a consumer-ready oral spray format built for everyday use within supplement guidelines

Where there is reduced access to GLP-1 RAs, support people with type 2 diabetes to access structured education and weight management programmes where available, it said